Nicholson y Cano, Hughes & Hughes and Cliffe Dekker Hofmeyr have advised San Miguel and its affiliated companies. Becker, Glynn, Muffly, Chassin & Hosinski LLP, Bruchou...
San Miguel Completes US$81 Million Refinancing and Upsizing of International Loan
Black Rock Coffee Bar Completes $338 Million Initial Public Offering
Jones Day has advised the founders of Black Rock Coffee Bar, Latham & Watkins has advised Black Rock Coffee Bar and Kirkland & Ellis has advised...
IFC Provides USD 100 Million Financing to Cogna Educação for Technology Investments
TozziniFreire Advogados and Becker, Glynn, Muffly, Chassin & Hosinski have advised International Finance Corporation (IFC). Lefosse Advogados has advised Cogna Educação S.A. The International Finance Corporation...
Pathos AI’s Acquisition of Rain Oncology
Leerink Partners is acting as exclusive financial advisor and Gibson, Dunn & Crutcher LLP is acting as legal counsel to Rain. Goodwin Procter LLP is acting...
Scholar Rock’s $92.5 Million Common Stock Offering
Goodwin advised Scholar Rock Holding Corporation on the offering. Scholar Rock Holding Corporation (Nasdaq: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious...
Kyowa Kirin’s $387 Million Acquisition of Orchard Therapeutics
Kyowa Kirin was represented by Goldman Sachs Japan Co., Ltd. as financial advisor and Morrison & Foerster LLP. as legal advisor. Orchard Therapeutics was represented by...
Nimbus Therapeutics’ $210 Million Private Financing
Goodwin advised Nimbus Therapeutics on the financing. Nimbus Therapeutics announced its $210 million private financing to advance its next wave of tech-enabled small molecule medicines. The...
Revolution Medicines’ Acquisition of EQRx
Latham & Watkins advises Revolution Medicines on the deal, and Goodwin Procter advises EQRx. Revolution Medicines, Inc. (Nasdaq: RVMD) and EQRx, Inc. (Nasdaq: EQRX) announced a definitive agreement...
Korro Bio and Frequency Therapeutics’ Merger Agreement
Goodwin Procter is serving as legal counsel to Korro Bio, Latham & Watkins is serving as Frequency Therapeutics’ legal counsel, and Davis Polk is serving as...
Akero Therapeutics’s $220 Million Registered Direct Offering
Goodwin advised Akero Therapeutics on the offering, and Cooley advised the underwriter involved. Akero Therapeutics (Nasdaq: AKRO) announced the closing of its underwritten registered direct offering...
Avadel Pharmaceuticals’ $75 Million Royalty Financing
Goodwin Procter advised Avadel Pharmaceutics on the deal. Avadel announced its royalty agreement with RTW Investments, LP and certain of its affiliates for up to $75 million....
Royalty Pharma’s Acquisition of Royalty Interest in SPINRAZA and Pelacarsen from Ionis
Fenwick and Goodwin represented Royalty Pharma on the deal. Royalty Pharma (Nasdaq: RPRX), a buyer of biopharmaceutical royalties and funder of innovation across the biopharmaceutical industry,...